March 2, 2020 / 1:57 PM / a month ago

BRIEF-Takeda Receives Positive CHMP Opinion For Alunbrig As A First-Line Treatment For ALK+ Non-Small Cell Lung Cancer

March 2 (Reuters) - Takeda Pharmaceutical Co Ltd:

* TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ALUNBRIG® (BRIGATINIB) AS A FIRST-LINE TREATMENT FOR ALK+ NON-SMALL CELL LUNG CANCER

* TAKEDA PHARMACEUTICAL CO LTD - POSITIVE CHMP OPINION FOR ALUNBRIG BASED ON DATA FROM PHASE 3 ALTA-1L TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below